(Q37884172)

24 August 2017

1 reference

title

Trends in safety pharmacology: posters presented at the annual meetings of the Safety Pharmacology Society 2001-2010. (English)

1 reference

24 August 2017

1 reference

William S Redfern

1

1 reference

24 August 2017

Jean-Pierre Valentin

series ordinal

2

1 reference

24 August 2017

publication date

25 May 2011

1 reference

Journal of Pharmacological and Toxicological Methods

24 August 2017

published in

1 reference

24 August 2017

volume

64

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

102-110

1 reference

Juvenile animal testing in drug development--is it useful?

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Exploratory drug safety: a discovery strategy to reduce attrition in development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Origins, practices and future of safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Introduction to nonclinical safety pharmacology and the safety pharmacology society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Cardiovascular parameters in anaesthetized guinea pigs: a safety pharmacology screening model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Benchmarking safety pharmacology regulatory packages and best practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Integration of safety pharmacology endpoints into toxicology studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Concordance of the toxicity of pharmaceuticals in humans and in animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

QT PRODACT: comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Principles of safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Safety pharmacology--a progressive approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

A framework to assess the translation of safety pharmacology data to humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

Safety and secondary pharmacology: successes, threats, challenges and opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.003

10.1016/J.VASCN.2011.05.003

7 January 2021

Identifiers

DOI

1 reference

24 August 2017

1 reference